An expanded study of blood and prostate cancer tissue samples from the same patients will be needed to distinguish between true- and false-negative results of our combined VTX-1-AdnaDetect assay and will need to include patients with lower tumor burden than in this study cohort, which was enriched for patients with high PSA. The gene discussed is KLK3; the disease is prostate cancer.